JP2001240603A - beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM - Google Patents
beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOMInfo
- Publication number
- JP2001240603A JP2001240603A JP2000054976A JP2000054976A JP2001240603A JP 2001240603 A JP2001240603 A JP 2001240603A JP 2000054976 A JP2000054976 A JP 2000054976A JP 2000054976 A JP2000054976 A JP 2000054976A JP 2001240603 A JP2001240603 A JP 2001240603A
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- branched
- alkali
- extract
- agaricus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】この出願の発明は、抗腫瘍活
性β−１，６−グルカンとアガリクス茸アルカリ抽出エ
キスに関するものである。さらに詳しくは、この出願の
発明は、抗腫瘍剤等の医薬品として、あるいは機能性の
飲食品等として有用な、抗腫瘍活性を有する新しいβ−
１，６−グルカンと、これを提供することのできるアガ
リクス茸のアルカリ抽出エキスに関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an anti-tumor activity β-1,6-glucan and an extract of an alkali extract of Agaricus mushroom. More specifically, the invention of this application provides a new β-antitumor active β- useful as a pharmaceutical such as an antitumor agent or as a functional food or drink.
The present invention relates to 1,6-glucan and an alkali extract of Agaricus mushroom which can provide the same.
【０００２】[0002]
【従来の技術と発明の課題】従来より、アガリクス茸は
様々な免疫賦活活性を有することが報告されており、こ
の出願の発明者らによっても、フェノール性高分子画分
がリンパ球幼若化活性並びに人株化細胞や人末梢血単核
球のＩＬ−８産生を増強することが報告されている。
このようなアガリクス茸の生理活性の特徴から、アガリ
クス茸の抽出エキスや粉末等が健康機能剤、あるいはそ
れらの飲食品として利用することが検討され、すでに各
種の態様として実用化されてもいる。2. Description of the Related Art Agaricus mushrooms have been reported to have various immunostimulatory activities, and the inventors of the present application have reported that the phenolic high-molecular fraction has lymphocyte blastogenesis. It has been reported to enhance the activity and IL-8 production of human cell lines and human peripheral blood mononuclear cells.
From the characteristics of the biological activity of Agaricus mushrooms, the use of extracts or powders of Agaricus mushrooms as health functional agents or their foods and drinks has been studied and has already been put into practical use in various modes.
【０００３】しかしながら、アガリクス茸には、β−
１，６−グルカンが含有されているとのことは様々な見
地より示唆されているものの、その分子構造と生理活性
との特徴のある関連性については依然として解明されて
いないのが実情である。このため、注目される生理活性
を有効に利用することや、アガリクス茸を産業的に利活
用を図ることには現実的に大きな制約があった。However, Agaricus mushrooms contain β-
Although it has been suggested from various viewpoints that 1,6-glucan is contained, the fact is that the characteristic relationship between the molecular structure and the physiological activity has not yet been elucidated. For this reason, there are practically great restrictions on effectively utilizing the physiological activity of interest and on the industrial use of agaricus mushrooms.
【０００４】この出願の発明は以上のとおりの事情に鑑
みてなされたものであって、アガリクス茸の産業的な利
活用をさらに図ることを可能とし、その生理活性を分子
構造の特徴との関連において利用できるものとする、新
しい方策と手段を提供することを課題としている。[0004] The invention of this application has been made in view of the circumstances described above, and makes it possible to further utilize the industrial use of Agaricus mushrooms, and relates the physiological activity to the characteristics of the molecular structure. It is an object of the present invention to provide new measures and means that can be used in the field.
【０００５】[0005]
【課題を解決するための手段】この出願の発明は、上記
の課題を解決するものとして、第１には、抗腫瘍活性を
示し、β−１，３−分岐構造を有していることを特徴と
するβ−１，３分岐β−１，６−グルカンを提供する。Means for Solving the Problems The invention of the present application is intended to solve the above-mentioned problems. First, the invention exhibits antitumor activity and has a β-1,3-branched structure. Provided is a β-1,3-branched β-1,6-glucan, which is a feature.
【０００６】また、この出願の発明は、第２には、アガ
リクス茸のアルカリ抽出エキスであることを特徴とする
β−１，３分岐β−１，６−グルカンを、第３には、ア
ルカリ抽出エキスが中性エキスであることを特徴とする
β−１，３分岐β−１，６−グルカンを、第４には、ア
ガリクス茸が寄託番号ＦＥＲＭ Ｐ−１７６９５のアガ
リクス茸であることを特徴とするβ−１，３分岐β−
１，６−グルカンを提供する。[0006] The invention of the present application also provides, secondly, β-1,3-branched β-1,6-glucan, which is an alkali extract of Agaricus mushrooms; Fourth, the extracted extract is a neutral extract, and β-1,3-branched β-1,6-glucan. Fourth, the agaricus mushroom is an agaricus mushroom having a deposit number of FERM P-17695. Β-1,3-branch β-
1,6-glucan is provided.
【０００７】そして、この出願の発明は、第５には、ア
ガリクス茸のアルカリ抽出エキスであって、抗腫瘍活性
を示すことを特徴とするアガリクス茸アルカリ抽出エキ
スを提供し、第６には、主としてβ−１，３−分岐構造
を有するβ−１，６−グルカンを含有することを特徴と
するアガリクス茸アルカリ抽出エキスを、第７には、中
性エキスであることを特徴とするアガリクス茸アルカリ
抽出エキスを、第８には、アガリクス茸が寄託番号ＦＥ
ＲＭ Ｐ−１７６９５のアガリクス茸であることを特徴
とするアガリクス茸アルカリ抽出エキスを提供する。[0007] Fifth, the invention of this application provides an alkali extract of Agaricus mushroom, which is characterized by exhibiting antitumor activity. Agaricus mushroom alkaline extract, which mainly contains β-1,6-glucan having a β-1,3-branched structure, and seventhly, Agaricus mushroom, which is a neutral extract Eighth, Agaricus mushroom was deposited with the deposit number FE.
Provided is an alkali extract of Agaricus mushroom, which is an Agaricus mushroom of RM P-17695.
【０００８】さらに、この出願の発明は、前記第１ない
し第４のいずれかのβ−１，６−グルカンを有効成分と
して含有することを特徴とする抗腫瘍剤を提供する。Further, the invention of this application provides an antitumor agent comprising any one of the above-mentioned first to fourth β-1,6-glucans as an active ingredient.
【０００９】[0009]
【発明の実施の形態】この出願の発明は、上記のとおり
の特徴をもつものであるが、以下にその実施の形態につ
いて説明する。BEST MODE FOR CARRYING OUT THE INVENTION The invention of this application has the features as described above, and embodiments thereof will be described below.
【００１０】まず、この出願の発明においては、抗腫瘍
活性を示し、β−１，３分岐の分子構造を有しているβ
−１，６−グルカンが提供される。このものは、直鎖の
β−１，６−グルカンに分岐としてβ−１，３−グルカ
ンが結合している構造として特徴的である。β−１，３
分岐は、たとえば、直鎖に連結しているβ−１，６−グ
ルカンの単一ユニット３〜１０個当り１個のβ−１，３
−グルカンユニットが分岐結合しているものとして例示
される。First, in the invention of the present application, a β-1,3-branched β-3,
-1,6-glucan is provided. This is characteristic as a structure in which β-1,3-glucan is linked as a branch to linear β-1,6-glucan. β-1,3
The branches are, for example, one β-1,3 per 3-10 single units of β-1,6-glucan linked linearly.
-It is exemplified as a glucan unit having a branched bond.
【００１１】その分子量としては、重量平均として、１
０4 〜１０10のレベルであることが考慮される。The molecular weight is 1 as a weight average.
Levels of 0 4 to 10 10 are considered.
【００１２】このようなβ−１，３分岐β−１，６−グ
ルカンは、アガリクス茸のアルカリ抽出エキスとしてこ
の発明において提供される。このアルカリ抽出は、たと
えばＮａＯＨ、ＫＯＨ等のアルカリ成分の水溶液を用い
て行うことができる。２０℃以下、より好ましくは１０
℃以下の温度での抽出として行われる冷アルカリ抽出、
あるいは３０℃以上の温度での熱アルカリ抽出、もしく
はその両方の組合わせとして行うこともできる。Such β-1,3-branched β-1,6-glucan is provided in the present invention as an alkali extract of Agaricus mushroom. This alkali extraction can be performed using, for example, an aqueous solution of an alkali component such as NaOH or KOH. 20 ° C or less, more preferably 10 ° C
Cold alkali extraction performed as an extraction at a temperature below ℃
Alternatively, it can be performed as hot alkali extraction at a temperature of 30 ° C. or higher, or a combination of both.
【００１３】さらにより実際的には、アガリクス茸の粉
砕脱脂したものを、水または熱水により抽出処理し、そ
の残渣分をアルカリ抽出することが考慮される。[0013] Even more practically, it is considered that a pulverized and defatted Agaricus mushroom is subjected to extraction treatment with water or hot water, and the residue is alkali-extracted.
【００１４】より望ましくは、この発明のβ−１，３分
岐β−１，６−グルカンは、アガリクス茸のアルカリ抽
出エキスのうちの水溶性の中性画分である。これによっ
て、顕著な抗腫瘍活性を示すβ−１，３分岐β−１，６
−グルカンが提供される。More preferably, the β-1,3-branched β-1,6-glucan of the present invention is a water-soluble neutral fraction of an alkali extract of Agaricus mushrooms. Thus, β-1,3-branched β-1,6 showing remarkable antitumor activity
-Glucan is provided.
【００１５】アガリクス茸については、各種の産生地や
方法で取得されるものとして考慮されるが、この出願の
発明においては、ブラジル露地栽培のアガリクス茸、な
かでも、寄託番号ＦＥＲＭ Ｐ−１７６９５としてのア
ガリクス茸（King-Agaricus21）が好適なものとして挙
げられる。[0015] Agaricus mushrooms are considered to be obtained at various production sites and methods. In the invention of this application, Agaricus mushrooms cultivated in Brazilian open-air cultivation, in particular, as accession number FERM P-17695 Agaricus mushroom (King-Agaricus21) is mentioned as a suitable thing.
【００１６】以上のようなこの出願の発明のβ−１，３
分岐β−１，６−グルカン、そして、アガリクス茸のア
ルカリ抽出エキスは、顕著な抗腫瘍活性を示すものとし
て特徴づけられる。このため、これらを有効成分として
抗腫瘍剤とすることや、あるいは機能性の飲食品として
提供することができる。The β-1,3 of the invention of this application as described above
Branched β-1,6-glucan and alkali extracted extracts of Agaricus mushrooms are characterized as exhibiting significant antitumor activity. Therefore, these can be used as an antitumor agent as an active ingredient, or provided as a functional food or drink.
【００１７】そこで以下に実施例を示し、さらに詳しく
この出願の発明について説明する。もちろん、以下の説
明によって発明が限定されることはない。The present invention will now be described in more detail with reference to the following examples. Of course, the invention is not limited by the following description.
【００１８】[0018]
【実施例】＜１＞ブラジル露地栽培のアガリクス茸（Ｆ
ＥＲＭ Ｐ−１７６９５）を粉砕脱脂し、その乾燥粉末
２５ｇを、５００ｍｌの水を用いてオートクレーブ中に
おいて２時間熱水抽出した。抽出残渣に対し、同様にし
て２回の熱水抽出を行い、熱水抽出画分（ＡｇＨＷＥ１
〜３）を収率１７％で得た。[Example] <1> Agaricus mushroom (F)
ERM P-17695) was pulverized and defatted, and 25 g of the dried powder was extracted with 500 ml of water in an autoclave for 2 hours with hot water. The extraction residue was subjected to hot water extraction twice in the same manner to obtain a hot water extraction fraction (AgHWE1).
To 3) were obtained with a yield of 17%.
【００１９】熱水抽出後の残渣分に対し、５％尿素添加
の１０％ＮａＯＨ水溶液５００ｍｌを用いて、４℃の温
度で１日抽出し、冷アルカリ抽出画分（ＡｇＣａ１）
１．８３ｇを得た。さらに残渣分に対して同様に抽出処
理し、冷アルカリ抽出画分（ＡｇＣＡ２）１．０７６ｇ
を得た。The residue after hot water extraction was extracted at a temperature of 4 ° C. for 1 day using 500 ml of a 10% aqueous NaOH solution containing 5% urea, and a cold alkali extraction fraction (AgCa1)
1.83 g were obtained. Further, the residue was similarly extracted, and 1.076 g of a cold alkali extracted fraction (AgCA2) was obtained.
I got
【００２０】次いで、さらにその残渣分に対して、６５
℃、１時間の条件で熱アルカリ抽出を行い、熱アルカリ
抽出画分（ＡｇＨＡ）０．７４ｇ（収率３％）を得た。Next, 65% of the residue
A hot alkali extraction was performed at 1 ° C. for 1 hour to obtain a hot alkali extraction fraction (AgHA) 0.74 g (yield 3%).
【００２１】＜２＞これらの画分の糖含有量と蛋白含有
量等を測定したところ次の表１のとおりであった。<2> The sugar content, protein content and the like of these fractions were measured and the results are as shown in Table 1 below.
【００２２】[0022]
【表１】 [Table 1]
【００２３】含有される糖の主構成糖はいずれの場合も
グルコースであった。The main constituent sugar of the sugar contained was glucose in each case.
【００２４】13Ｃ−ＮＭＲによって、いずれの場合に
も、主にβ−１，６−グルカンに帰属されるシグナルが
確認された。図１、図２および図３は、前記冷アルカリ
抽出画分（ＡｇＣＡ１）（ＡｇＣＡ２）および熱アルカ
リ抽出画分（ＡｇＨＡ）の13Ｃ−ＮＭＲスペクトルを示
したものである。By 13 C-NMR, in each case, a signal mainly belonging to β-1,6-glucan was confirmed. FIGS. 1, 2 and 3 show the 13 C-NMR spectra of the above-mentioned cold alkali extraction fraction (AgCA1) (AgCA2) and hot alkali extraction fraction (AgHA).
【００２５】＜３＞前記の冷アルカリ抽出画分（ＡｇＣ
Ａ１）（ＡｇＣＡ２）および熱アルカリ抽出画分（Ａｇ
ＨＡ）について、β−１，３−グルカンの特異的検出試
薬であるリムルスＧテストとの反応性を評価した。その
結果、この反応性はいずれも低いことが確認された。ま
た、この反応性は、β−１，３−グルカン分解酵素であ
るZymolyase 処理でもほとんど変化しないことが確認さ
れた。<3> The above-mentioned cold alkali extraction fraction (AgC
A1) (AgCA2) and hot alkali extract fraction (AgCA2)
HA) was evaluated for its reactivity with Limulus G test, which is a specific detection reagent for β-1,3-glucan. As a result, it was confirmed that the reactivity was low. In addition, it was confirmed that the reactivity hardly changed by the treatment with Zymolyase which is a β-1,3-glucan degrading enzyme.
【００２６】このことから、各画分は、β−１，３−グ
ルカンを主構成としていないことが推察された。From this, it was inferred that each fraction did not mainly consist of β-1,3-glucan.
【００２７】＜４＞前記の熱水抽出画分（ＡｇＨＷ）を
含めて各画分をSarcoma １８０担癌マウスの腹腔内に頻
回投与し、抗腫瘍効果を評価した。その結果を表２に示
した。<4> Each fraction including the above-mentioned hot water-extracted fraction (AgHW) was frequently administered intraperitoneally to Sarcoma 180 tumor-bearing mice, and the antitumor effect was evaluated. The results are shown in Table 2.
【００２８】[0028]
【表２】 [Table 2]
【００２９】この結果から、冷アルカリ抽出画分（Ａｇ
ＣＡ１）（ＡｇＣＡ２）および熱アルカリ抽出画分（Ａ
ｇＨＷ）は、ＶＤＨ反応を示すとともに腫瘍増殖を著し
く抑制すること（腫瘍増殖抑制率＞９０％）が確認され
た。一方、熱水抽出画分（ＡｇＨＷ）には、このような
活性は認められなかった。From the results, it was found that the cold alkali extraction fraction (Ag
CA1) (AgCA2) and hot alkali extract fraction (A
gHW) showed a VDH reaction and markedly suppressed tumor growth (tumor growth inhibition rate> 90%). On the other hand, such activity was not observed in the hot water extracted fraction (AgHW).
【００３０】＜５＞前記の活性は、中性画分において認
められ、β−１，３−グルカナーゼ＜Zymolyase ＞処理
によっても消失しなかった。<5> The above activity was observed in the neutral fraction, and was not lost even by β-1,3-glucanase <Zymolyase> treatment.
【００３１】さらに、冷アルカリ抽出画分（ＡｇＣＡ
１）（ＡｇＣＡ２）を中性条件下に可溶部と不溶部に分
画したところ、活性は可溶部で強いことが確認された。
なお、アルカリ抽出画分は、いったんアルカリ抽出する
と中和しても水溶性である。Further, a cold alkali extraction fraction (AgCA
1) When (AgCA2) was fractionated into a soluble part and an insoluble part under neutral conditions, it was confirmed that the activity was strong in the soluble part.
The alkali-extracted fraction is water-soluble even after being neutralized once with alkali.
【００３２】また、次亜塩素酸酸化によって除タンパク
しても活性は維持されていることが確認された。Further, it was confirmed that the activity was maintained even when the protein was removed by hypochlorite oxidation.
【００３３】以上のことから、β−１，６−グルカンが
主たる活性中心である可能性が推察されたが、直鎖β−
１，６−グルカンであるイスランジカンは活性を示さな
いことがすでに報告されていることから、さらに分子構
造と活性との関係について検討した。From the above, it was inferred that β-1,6-glucan may be the main active center, but it was found that
It has already been reported that 1,6-glucan islandican does not show activity, so the relationship between molecular structure and activity was further investigated.
【００３４】＜６＞そこで、 1Ｈ−ＮＭＲにより分析し
たところ、分岐点の存在（たとえば熱アルカリ抽出画分
（ＡｇＨＡ）について示した図４、特にＡ点）が示唆さ
れた。<6> Then, analysis by 1 H-NMR suggested the presence of a branch point (for example, FIG. 4 showing the hot alkali extraction fraction (AgHA), particularly point A).
【００３５】また、抗分岐β−グルカン特異的抗体での
検出を試みたところ、抗体との有意な反応性を示すこと
が確認された。When an attempt was made to detect the antibody with an anti-branched β-glucan-specific antibody, it was confirmed that the antibody showed significant reactivity with the antibody.
【００３６】以上のことから、抗腫瘍活性を示すアルカ
リ抽出画分は、β−１，３分岐のβ−１，６−グルカン
を含むものであることが確認された。From the above, it was confirmed that the alkali-extracted fraction exhibiting antitumor activity contained β-1,3-branched β-1,6-glucan.
【００３７】なお、以上の実施例での熱アルカリ抽出画
分の分子量は約１×１０7 であった。The molecular weight of the hot alkali-extracted fraction in the above Examples was about 1 × 10 7 .
【００３８】[0038]
【発明の効果】以上詳しく説明したとおり、この出願の
発明によって、抗腫瘍活性を示し、β−１，３−分岐β
−１，６−グルカン並びにこれを含有するアガリクス茸
アルカリ抽出エキスが提供される。これによって、アガ
リクス茸の産業的な利活用をさらに図ることを可能と
し、その生理活性を分子構造の特徴との関連において利
用できるものとする、新しい方策と手段が提供される。As described above in detail, the invention of this application shows an antitumor activity and a β-1,3-branched β
-1,6-glucan and agaricus mushroom alkali extract containing the same are provided. This provides new strategies and means to further exploit the industrial use of Agaricus mushrooms and to make their bioactivity available in relation to the features of the molecular structure.
【図１】実施例としての冷アルカリ抽出画分（ＡｇＣＡ
１）の13Ｃ−ＮＭＲスペクトル図である。FIG. 1 shows a cold alkali-extracted fraction (AgCA
It is a 13 C-NMR spectrum figure of 1).
【図２】冷アルカリ抽出画分（ＡｇＣＡ２）の13Ｃ−Ｎ
ＭＲスペクトル図である。FIG. 2: 13 C—N of a cold alkali extracted fraction (AgCA2)
It is an MR spectrum figure.
【図３】熱アルカリ抽出画分（ＡｇＨＡ）の13Ｃ−ＮＭ
Ｒスペクトル図である。FIG. 3. 13 C-NM of hot alkali extracted fraction (AgHA)
It is an R spectrum figure.
【図４】熱アルカリ抽出画分（ＡｇＨＡ）の 1Ｈ−ＮＭ
Ｒのスペクトル図である。FIG. 4. 1 H-NM of hot alkali extracted fraction (AgHA)
It is a spectrum diagram of R.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 35/00 Ａ６１Ｐ 35/00 ４Ｃ０９０ // Ｃ１２Ｎ 1/14 Ｃ１２Ｎ 1/14 Ｅ Ｃ１２Ｐ 1/02 Ｃ１２Ｐ 1/02 Ｂ 19/04 19/04 Ｂ (Ｃ１２Ｎ 1/14 (Ｃ１２Ｎ 1/14 Ｅ Ｃ１２Ｒ 1:645） Ｃ１２Ｒ 1:645） (Ｃ１２Ｐ 1/02 (Ｃ１２Ｐ 1/02 Ｂ Ｃ１２Ｒ 1:645） Ｃ１２Ｒ 1:645） (Ｃ１２Ｐ 19/04 (Ｃ１２Ｐ 19/04 Ｂ Ｃ１２Ｒ 1:645） Ｃ１２Ｒ 1:645） Ｆターム(参考） 4B018 LE05 MD33 MD82 ME08 MF01 MF11 4B064 AF12 AH19 CA07 CE08 DA05 4B065 AA71X AC14 BD16 CA22 CA41 CA44 4C086 AA01 AA02 AA04 EA21 MA52 NA14 ZB26 4C088 AA07 AC17 BA09 CA05 MA52 NA14 ZB26 4C090 AA09 BA23 BA35 BB04 BB12 BB33 BB35 BB38 BB52 BB92 BC18 CA01 CA04 CA33 DA23──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 35/00 A61P 35/00 4C090 // C12N 1/14 C12N 1/14 E C12P 1/02 C12P 1 / 02 B 19/04 19/04 B (C12N 1/14 (C12N 1/14 E C12R 1: 645) C12R 1: 645) (C12P 1/02 (C12P 1/02 B C12R 1: 645) C12R 1: 645 ) (C12P 19/04 (C12P 19/04 B C12R 1: 645) C12R 1: 645) F term (reference) 4B018 LE05 MD33 MD82 ME08 MF01 MF11 4B064 AF12 AH19 CA07 CE08 DA05 4B065 AA71X AC14 BD16 CA22 CA41 CA44 4C086 AA01 AA02 AA04 EA21 MA52 NA14 ZB26 4C088 AA07 AC17 BA09 CA05 MA52 NA14 ZB26 4C090 AA09 BA23 BA35 BB04 BB12 BB33 BB35 BB38 BB52 BB92 BC18 CA01 CA04 CA33 DA23
Claims (9)
造を有していることを特徴とするβ−１，３分岐β−
１，６−グルカン。1. A β-1,3-branched β-character having an antitumor activity and having a β-1,3-branched structure.
1,6-glucan.
ることを特徴とする請求項１のβ−１，３分岐β−１，
６−グルカン。2. The β-1, 3-branched β-1, β-1, 3-branched extract according to claim 1, wherein the extract is an alkali extract of Agaricus mushrooms.
6-glucan.
ことを特徴とする請求項２のβ−１，３分岐β−１，６
−グルカン。3. The β-1,3-branched β-1,6 according to claim 2, wherein the alkali extract is a neutral extract.
-Glucan.
１７６９５のアガリクス茸であることを特徴とする請求
項２または３のβ−１，３分岐β−１，６−グルカン。4. Agaricus mushroom having a deposit number of FERM P-
The β-1,3-branched β-1,6-glucan according to claim 2 or 3, which is 17695 Agaricus mushroom.
って、抗腫瘍活性を示すことを特徴とするアガリクス茸
アルカリ抽出エキス。5. An alkali extract of Agaricus mushroom, which has an antitumor activity.
β−１，６−グルカンを含有することを特徴とする請求
項５のアガリクス茸アルカリ抽出エキス。6. The alkali extract of Agaricus mushrooms according to claim 5, which comprises mainly β-1,6-glucan having a β-1,3-branched structure.
項５または６のアガリクス茸アルカリ抽出エキス。7. The extract of an alkali extracted from Agaricus mushrooms according to claim 5, which is a neutral extract.
１７６９５のアガリクス茸であることを特徴とする請求
項５ないし７のいずれかのアガリクス茸アルカリ抽出エ
キス。8. Agaricus mushroom having a deposit number of FERM P-
The Agaricus mushroom alkaline extract according to any one of claims 5 to 7, which is 17695 Agaricus mushroom.
６−グルカンを有効成分として含有することを特徴とす
る抗腫瘍剤。9. The method according to claim 1, wherein
An antitumor agent comprising 6-glucan as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000054976A JP2001240603A (en) | 2000-02-29 | 2000-02-29 | beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000054976A JP2001240603A (en) | 2000-02-29 | 2000-02-29 | beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001240603A true JP2001240603A (en) | 2001-09-04 |
Family
ID=18576167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000054976A Pending JP2001240603A (en) | 2000-02-29 | 2000-02-29 | beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001240603A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004043441A (en) * | 2002-05-15 | 2004-02-12 | Bhn Kk | Neovascularization inhibitor and its utilization |
| US7838052B2 (en) | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Pine cone extracts and uses thereof |
| US7838046B2 (en) | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Plant extracts and uses thereof |
| US7977379B2 (en) | 2002-05-15 | 2011-07-12 | Bhn Co., Ltd. | Method for angiogenesis inhibition or immunostimulation |
| JP2023005235A (en) * | 2021-06-28 | 2023-01-18 | 東栄新薬株式会社 | Akkermansia muciniphila proliferation promoting composition applicable for medical and cosmetic uses, and pharmaceuticals, food and drink, and feed comprising the same |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5574797A (en) * | 1978-12-04 | 1980-06-05 | Mitsubishi Yuka Yakuhin Kk | Preparation of protein polysaccharide having anti-tumor activity |
| JPS6467195A (en) * | 1987-09-07 | 1989-03-13 | Nichirei Kk | Production of neutral polysaccharide substance having antitumor action |
| JPS6467194A (en) * | 1987-09-07 | 1989-03-13 | Nichirei Kk | Production of acidic polysaccharide substance having antitumor action |
| JPH0278630A (en) * | 1988-09-14 | 1990-03-19 | Nichirei Corp | Antitumor agent |
| JPH02203765A (en) * | 1989-02-02 | 1990-08-13 | Nippon Beet Sugar Mfg Co Ltd | Food having antitumor function and production thereof |
| JPH069423A (en) * | 1992-06-19 | 1994-01-18 | Sumitomo Ringyo Kk | Antitumor substance |
| JPH06128164A (en) * | 1992-10-16 | 1994-05-10 | Hitoshi Ito | Oral administration agent, beverage and food having anti-cancer activity |
| JPH09316104A (en) * | 1996-05-29 | 1997-12-09 | Yoshiyasu Kitani | Novel phosphorylated beta-glucan with anti-aids viral activity and drug for treating retrovirus infectious disease |
| JPH11279204A (en) * | 1998-03-27 | 1999-10-12 | Sumitomo Forestry Co Ltd | Immunosuppressant |
| JP2001103927A (en) * | 1999-10-09 | 2001-04-17 | Bizen Kasei Kk | Method of producing agaricus blazei murill extract having high antitumor activity |
-
2000
- 2000-02-29 JP JP2000054976A patent/JP2001240603A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5574797A (en) * | 1978-12-04 | 1980-06-05 | Mitsubishi Yuka Yakuhin Kk | Preparation of protein polysaccharide having anti-tumor activity |
| JPS6467195A (en) * | 1987-09-07 | 1989-03-13 | Nichirei Kk | Production of neutral polysaccharide substance having antitumor action |
| JPS6467194A (en) * | 1987-09-07 | 1989-03-13 | Nichirei Kk | Production of acidic polysaccharide substance having antitumor action |
| JPH0278630A (en) * | 1988-09-14 | 1990-03-19 | Nichirei Corp | Antitumor agent |
| JPH02203765A (en) * | 1989-02-02 | 1990-08-13 | Nippon Beet Sugar Mfg Co Ltd | Food having antitumor function and production thereof |
| JPH069423A (en) * | 1992-06-19 | 1994-01-18 | Sumitomo Ringyo Kk | Antitumor substance |
| JPH06128164A (en) * | 1992-10-16 | 1994-05-10 | Hitoshi Ito | Oral administration agent, beverage and food having anti-cancer activity |
| JPH09316104A (en) * | 1996-05-29 | 1997-12-09 | Yoshiyasu Kitani | Novel phosphorylated beta-glucan with anti-aids viral activity and drug for treating retrovirus infectious disease |
| JPH11279204A (en) * | 1998-03-27 | 1999-10-12 | Sumitomo Forestry Co Ltd | Immunosuppressant |
| JP2001103927A (en) * | 1999-10-09 | 2001-04-17 | Bizen Kasei Kk | Method of producing agaricus blazei murill extract having high antitumor activity |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838052B2 (en) | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Pine cone extracts and uses thereof |
| US7838046B2 (en) | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Plant extracts and uses thereof |
| JP2004043441A (en) * | 2002-05-15 | 2004-02-12 | Bhn Kk | Neovascularization inhibitor and its utilization |
| JP4681801B2 (en) * | 2002-05-15 | 2011-05-11 | ビーエイチエヌ株式会社 | Angiogenesis inhibitor and method for producing the same |
| US7977379B2 (en) | 2002-05-15 | 2011-07-12 | Bhn Co., Ltd. | Method for angiogenesis inhibition or immunostimulation |
| JP2023005235A (en) * | 2021-06-28 | 2023-01-18 | 東栄新薬株式会社 | Akkermansia muciniphila proliferation promoting composition applicable for medical and cosmetic uses, and pharmaceuticals, food and drink, and feed comprising the same |
| JP7398714B2 (en) | 2021-06-28 | 2023-12-15 | 東栄新薬株式会社 | Akkermansia muciniphila proliferation-promoting composition applicable to medical and beauty treatments, as well as pharmaceuticals, food and beverages, and feed containing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sone et al. | Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum | |
| Zhang et al. | Evaluation of mushroom dietary fiber (nonstarch polysaccharides) from sclerotia of Pleurotus tuber-regium (Fries) Singer as a potential antitumor agent | |
| Oshima et al. | Isolation and hypoglycemic activity of quinquefolans A, B, and C, glycans of Panax quinquefolium roots | |
| Ramesh et al. | Effect of fenugreek (Trigonella foenum-graecum L.) galactomannan fractions on phagocytosis in rat macrophages and on proliferation and IgM secretion in HB4C5 cells | |
| CA2650938A1 (en) | Non-starchy rice bran polysaccharides | |
| CN1133654C (en) | Carboxynethylated derivative of ganoderic alpha-(1-3)-D-glucosan and its usage and preparing process | |
| JP2011026525A (en) | METHOD FOR EXTRACTING POLYSACCHARIDE COMPRISING beta-GLUCAN AS MAIN COMPONENT | |
| JP2001240603A (en) | beta-1,3-BRANCHED beta-1,6-GLUCAN AND ALKALI EXTRACTED ESSENCE OF AGARICUS MUSHROOM | |
| CN109939132A (en) | The concocting method and application thereof of rare ginsenoside content in a kind of increase ginseng | |
| JP2000217543A (en) | SPARASSIS CRISPA Fr. EXTRACT | |
| WO2008032134A1 (en) | Method for obtaining yeast glucan by autolysis of saccharomyces cerevisiae baker's yeast cells | |
| CN102936611B (en) | Collagen extracted from black butterflyfish skins with scales and application of collagen | |
| Zhuang et al. | Chemical modification and antitumor activity of polysaccharides from the mycelium of liquid-cultured Grifola frondosa | |
| TW201806965A (en) | Polysaccharide having natural immunostimulatory action and natural immunostimulant or food or drink comprising same | |
| Suzuki et al. | Immunopharmacological activity of the purified insoluble glucan, zymocel, in mice | |
| JP4451100B2 (en) | Immunostimulant and anticancer agent containing Tamogitake fruit body composition as active ingredient | |
| US20230355685A1 (en) | Raw material production from stichopus variegatus | |
| WO2003070264A1 (en) | Anion exchange resin adsorbed fraction, immunopotentiator and promoter for recovery from loaded stress originating in matsutake mushroom | |
| CN1133653C (en) | Ganoderic alpha-(1-3)-D-glucosan sulfate derivative and its usage and preparing process | |
| Aminin et al. | Cytotoxic action of triterpene glycosides from sea cucumbers from the genus Cucumaria on mouse spleen lymphocytes. Inhibition of nonspecific esterase | |
| Ovodov | Bioglycans and natural glycosides as a promising research topic in bioorganic chemistriy | |
| KR101116247B1 (en) | Physiologically acitive materials from rice bran and process for preparation thereof | |
| KR100729213B1 (en) | Exo-biopolymer isolated from submerged mycelial culture of Grifola frondosa increasing immune activity | |
| KR100543692B1 (en) | Dissolution method of insoluble ?-glucan separated from basidiomycetes | |
| JP2009143854A (en) | Wound-healing promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100525 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101005 |